domingo, 20 de octubre de 2013

The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience : Genetics in Medicine : Nature Publishing Group

The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience : Genetics in Medicine : Nature Publishing Group


The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience

Journal name:
Genetics in Medicine
(2013)
DOI:
doi:10.1038/gim.2013.160
Received
Accepted
Published online

Abstract

Purpose:

The advent of next-generation sequencing for cancer susceptibility genes holds promise for clinical genetics application, but the practical issues surrounding integration of this testing into the clinical setting have not been well addressed. This article describes the clinical experience of genetic counselors in an academic and community setting with next-generation sequencing cancer panels.

Methods:

Between April 2012 and January 2013, 60 next-generation sequencing panels were ordered. A retrospective review was conducted to determine the indication for ordering the results of the tests and the patient management based on the results.

Results:

Ten tests were canceled due to out-of-pocket costs or previously identified mutations. Among the 50 tests, 5 (10%) showed a positive result. Moreover, 15 of the 50 (30%) panels detected variant(s) of uncertain significance or variant(s) suspected benign.

Conclusion:

We propose clinical guidelines for identifying high-risk patients who should be offered this testing. Our data support the National Comprehensive Cancer Network recommendations that next-generation sequencing be ordered as a second-tier test for high-risk individuals with cancer by trained cancer genetics providers. Literature review and expert knowledge should be used to create management plans for the identification of both positive and variants of uncertain significance results. Providers should be aware of limitations regarding reimbursement for testing and recommended management strategies.
Genet Med advance online publication 10 October 2013
View full text

Keywords:

BRCA; genetic testing; genomics; next-generation sequencing; panel testing

References

  1. Meder B, Haas J, Keller A, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 2011;4:110–122.
  2. Lin X, Tang W, Ahmad S, et al. Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities. Hear Res 2012;288:67–76.
  3. Ambry Genetics, 2013. Hereditary cancer panels. http://ambrygenetics.com/next-gen-cancer-panels Accessed 1 July 2013.
  4. Ambry Genetics, 2012. The case for clinical adoption of hereditary breast cancer panel testing. http://www.ambrygen.com/sites/default/files/pdfs/cancer%20forms/BreastNext_WhitePaper_100412.pdf Accessed 1 July 2013.
  5. National Comprehensive Cancer Network, Inc., 2013. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2013. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf Accessed 8 March 2013.
  6. Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013;119:332–338.
  7. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379–1388.
  8. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011;108:18032–18037.
  9. Silvestri V, Rizzolo P, Falchetti M, et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 2011;13:404.
  10. Loveday C, Turnbull C, Ruark E, et al.; Breast Cancer Susceptibility Collaboration (UK). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012;44:475–476; author reply 476.
  11. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410–414.
  12. Ahmed M and Rahman N. ATM and breast cancer susceptibility. Hum Mutat 2006; 27:1122–1128.
  13. Renwick A, Thompson D, Seal S, et al.; Breast Cancer Susceptibility Collaboration (UK). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873–875.
  14. Bernstein JL, Teraoka S, Southey MC, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat 2006;27:1122–1128.
  15. Gutiérrez-Enríquez S, Fernet M, Dörk T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 2004;40:109–119.
  16. Mao JH, Wu D, DelRosario R, Castellanos A, Balmain A, Perez-Losada J. Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background. Oncogene 2008;27:6596–6600.
  17. Angèle S, Falconer A, Edwards SM, et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 2004;91:783–787.
  18. CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004;74:1175–1182.
  19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652–1662.
  20. Cybulski C, Wokolorczyk D, Huzarski T, et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006;43:863–866.
  21. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.
  22. Cybulski C, Górski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131–1135.
  23. Szymanska-Pasternak J, Szymanska A, Medrek K, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006;102:429–431.
  24. Xiang HP, Geng XP, Ge WW, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer 2011;47:2546–2551.
Download references

Author information

Affiliations

  1. Department of Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    • Caitlin B. Mauer

  2. Department of Cancer Genetics, Moncrief Cancer Institute, University of Texas Southwestern Medical Center, Fort Worth, Texas, USA

    • Sara M. Pirzadeh-Miller

  3. Department of Cancer Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    • Linda D. Robinson

  4. Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    • David M. Euhus

Corresponding author

Correspondence to:
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)